G.ST Antivirals reaches a major milestone in the development of its lead asset and begins clinical phase I at the Vienna General Hospital

G.ST Antivirals to expand its innovative host cell-based treatment approach to COPD exacerbations after succeeding in highly competitive Life science call of the Vienna Business Agency

CEO and Co-founder Guido Gualdoni talked at the Gründer&Zünder Podcast about the exciting path from scientific findings to starting a biotech company

G.ST Antiviral's founder gave an encouraging interview about the obstacles and joys of founding a university spin-off (in German)

Founders of G.ST Antivirals Guido Gualdoni and Johannes Stöckl are “Inventors of the Year 2020” of the Medical University of Vienna

Viennese biotech startup G.ST Antivirals gets funding for viral disease therapies

G.ST Antivirals and Takeda start research cooperation on antivirals against COVID-19